ALLAKOS INC (ALLK) Stock News
NASDAQ:ALLK - Nasdaq - US01671P1003 - Common Stock - Currency: USD
ALLK Latest News, Press Releases and Analysis
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.
On Friday, there are stocks with unusual volume. Let's take a look.
The trading volume of these stocks is deviating from the norm in today's session.
The trading volume of these stocks is deviating from the norm in today's session.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.
Get insights into the top gainers and losers of Tuesday's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Which stocks are experiencing notable movement on Monday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade
The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.
Why Is Allakos Stock Plunging On Monday?
Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 million in estimated costs.
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Traders are paying attention to the gapping stocks in Monday's session.
Let's have a look at the gap up and gap down stocks in today's session.
These stocks that are showing activity before the opening bell on Monday.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore...
Top movers in Monday's after hours session
Monday's after hours session: top gainers and losers
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK)...
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was...
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
ALLK stock results show that Allakos beat analyst estimates for earnings per share the second quarter of 2024.
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the second quarter of 2024.Alla...
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects...
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a...
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
ALLK stock results show that Allakos met analyst estimates for earnings per share the first quarter of 2024.
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the first quarter of 2024.Allak...
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!